News

JANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTS

  • LAS VEGAS , July 12, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on fintech and healthcare, confirmed today that, as of market open on Monday, July 15, 2024, the Company's new name will be "ALT5 Sigma Corporation" and its Nasdaq common stock ticker symbol will change to "ALTS". This will replace the Company's current ticker symbol "JAN".
    07/12/2024

JanOne Announces Plan to Enhance Stockholder Value Through Strategic Realignment

  • -The board has approved a strategic review of the biotech assets and ALT5 Sigma being the core focus going forward- -The company is intending a name and stock symbol change to reflect this decision- LAS VEGAS , July 10, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on fintech and healthcare, has announced plans to enhance stockholder value through a visionary strategic realignment, entailing a redeployment of biotech assets and a change of its name. The plan, unanimously approved by the company's board and following the May acquisition of fintech innovator, ALT5 Sigma, is intended to complete a strategic review with the goal of monetizing the company's biotech assets.
    07/10/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

JanOne Inc. (JAN) can hold. Click on Rating Page for detail.

The price of JanOne Inc. (JAN) is 2.23 and it was updated on 2024-07-27 07:02:14.

Currently JanOne Inc. (JAN) is in undervalued.

News
    
News

3 Fintech Stocks to Sell in July Before They Crash & Burn

  • Investors should always be aware of their current positioning in the market cycle, especially when considering fintech stocks to sell. AI greatly propelled market expansion, so much so that just 10 top stocks in the S&P 500 make up 34% of the index, breaking the previous market concentration record all the way back in the 1920s.
    Mon, Jul. 08, 2024

JanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 Sigma

  • LAS VEGAS , June 26, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, is pleased to announce that it has appointed Mr. Vay Tham as its Chief Revenue Officer and President of ALT5 Sigma, Inc., its wholly-owned subsidiary.
    Wed, Jun. 26, 2024

ALT5 SIGMA, A JANONE COMPANY, ADDS PREPAID VISA®️ CARD INTEGRATION TO ALT5 SETTLEMENT PLATFORM

  • LAS VEGAS, June 25, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that its wholly-owned subsidiary, ALT5 Sigma, has launched its prepaid VISA®️ Card as an extension to the previously announced ALT5 Settlement Platform. ALT5 continues to expand its digital fintech offering in the crypto world to provide functionality from traditional legacy financial models in a modernized world.
    Tue, Jun. 25, 2024

JanOne's Subsidiary, Alt5, Reports 91% year over year increase in Transaction Volume to US $289 million for April and May 2024

  • LAS VEGAS , June 13, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, released today its wholly-owned subsidiary, ALT5 Sigma, transaction volume for April and May 2024. According to the Company, ALT5 Sigma transaction volume reached US$289 million for the months of April and May 2024 combined, compared to US$151 million in transaction volume for the months of April and May 2023 combined, representing a year-over-year increase of 91%.
    Thu, Jun. 13, 2024

ALT5 Sigma, a wholly-owned subsidiary of JanOne, Launches ALT5 Settlement Platform aimed at the untapped $27.3 Billion Global Digital Content Creation Market

  • LAS VEGAS , June 11, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that its wholly-owned subsidiary, ALT5 Sigma, has launched a new service named "ALT5 Settlement Platform" aimed at the untapped Global Digital Content Creation Market. According to JanOne, ALT5 Settlement Platform enables Digital Platforms with the ability instantaneously to pay all content creators in a cryptocurrency of their choice through ALT5 Settlement Platform APIs, including, but not limited to, Bitcoin, Ether, USDT, and USDC.
    Tue, Jun. 11, 2024
SEC Filings
SEC Filings

JanOne Inc. (JAN) - 424B5

  • SEC Filings
  • 06/21/2024

JanOne Inc. (JAN) - 424B5

  • SEC Filings
  • 05/23/2024

JanOne Inc. (JAN) - 424B5

  • SEC Filings
  • 05/06/2024

JanOne Inc. (JAN) - S-8

  • SEC Filings
  • 04/30/2024

JanOne Inc. (JAN) - EFFECT

  • SEC Filings
  • 04/26/2024

JanOne Inc. (JAN) - S-3

  • SEC Filings
  • 04/18/2024

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 08/28/2023

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 08/24/2023

JanOne Inc. (JAN) - 424B5

  • SEC Filings
  • 08/22/2023

JanOne Inc. (JAN) - PRE 14A

  • SEC Filings
  • 08/16/2023

JanOne Inc. (JAN) - SC 13G

  • SEC Filings
  • 03/27/2023

JanOne Inc. (JAN) - 424B5

  • SEC Filings
  • 03/24/2023

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 01/09/2023

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 10/06/2022

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/11/2022

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/03/2022

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 10/05/2021

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/26/2021

JanOne Inc. (JAN) - S-8

  • SEC Filings
  • 03/30/2021

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 03/10/2021

JanOne Inc. (JAN) - SC 13D

  • SEC Filings
  • 02/19/2021

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 02/11/2021

JanOne Inc. (JAN) - SC 13G

  • SEC Filings
  • 02/09/2021

JanOne Inc. (JAN) - SC 13G

  • SEC Filings
  • 02/08/2021

JanOne Inc. (JAN) - 424B5

  • SEC Filings
  • 02/02/2021

JanOne Inc. (JAN) - SC 13G

  • SEC Filings
  • 02/01/2021

JanOne Inc. (JAN) - EFFECT

  • SEC Filings
  • 12/30/2020

JanOne Inc. (JAN) - EFFECT

  • SEC Filings
  • 12/29/2020

JanOne Inc. (JAN) - CORRESP

  • SEC Filings
  • 12/29/2020

JanOne Inc. (JAN) - UPLOAD

  • SEC Filings
  • 12/28/2020

JanOne Inc. (JAN) - S-3

  • SEC Filings
  • 12/23/2020

JanOne Inc. (JAN) - RW

  • SEC Filings
  • 11/19/2020

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 10/02/2020

JanOne Inc. (JAN) - S-3

  • SEC Filings
  • 09/18/2020

JanOne Inc. (JAN) - PRE 14A

  • SEC Filings
  • 09/03/2020

JanOne Inc. (JAN) - 4/A

  • SEC Filings
  • 09/03/2020

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 09/03/2020

JanOne Inc. (JAN) - SC 13G

  • SEC Filings
  • 05/18/2020

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 01/10/2020

JanOne Inc. (JAN) - DEFR14A

  • SEC Filings
  • 10/18/2019

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 10/02/2019

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 09/12/2019

JanOne Inc. (JAN) - SC 13G

  • SEC Filings
  • 04/30/2019

JanOne Inc. (JAN) - 4/A

  • SEC Filings
  • 04/30/2019

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 04/30/2019

JanOne Inc. (JAN) - SC 13D

  • SEC Filings
  • 04/12/2019

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 09/18/2018

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 09/12/2018

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 09/11/2018

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 09/07/2018

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/30/2018

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 08/28/2018

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/27/2018

JanOne Inc. (JAN) - PRE 14A

  • SEC Filings
  • 08/24/2018

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/24/2018

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/14/2018

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 08/14/2018

JanOne Inc. (JAN) - S-8

  • SEC Filings
  • 08/10/2018

JanOne Inc. (JAN) - SC 13G

  • SEC Filings
  • 06/13/2018

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 10/25/2017

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 10/12/2017

JanOne Inc. (JAN) - PRE 14A

  • SEC Filings
  • 10/10/2017

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 10/05/2017

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 08/29/2017

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/24/2017

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 04/13/2017

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 03/31/2017

JanOne Inc. (JAN) - UPLOAD

  • SEC Filings
  • 12/14/2016

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 11/18/2016

JanOne Inc. (JAN) - CORRESP

  • SEC Filings
  • 11/18/2016

JanOne Inc. (JAN) - PRE 14A

  • SEC Filings
  • 11/01/2016

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 10/19/2016

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 08/23/2016

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/27/2016

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 01/29/2016

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 10/05/2015

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 10/05/2015

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 09/29/2015

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 09/28/2015

JanOne Inc. (JAN) - SC 13D

  • SEC Filings
  • 09/22/2015

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 09/21/2015

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 09/03/2015

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 07/09/2015

JanOne Inc. (JAN) - 3/A

  • SEC Filings
  • 05/29/2015

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 05/28/2015

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 04/14/2015

JanOne Inc. (JAN) - SC 13G

  • SEC Filings
  • 03/11/2015

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 02/18/2015

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 02/18/2015

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 02/04/2015

JanOne Inc. (JAN) - 5

  • SEC Filings
  • 02/03/2015

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 02/03/2015

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 01/26/2015

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 01/16/2015

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 01/07/2015

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 12/29/2014

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 12/19/2014

JanOne Inc. (JAN) - SC 13D

  • SEC Filings
  • 12/18/2014

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/13/2014

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 03/27/2014

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 03/12/2014

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 02/27/2014

JanOne Inc. (JAN) - UPLOAD

  • SEC Filings
  • 02/20/2014

JanOne Inc. (JAN) - CORRESP

  • SEC Filings
  • 02/10/2014

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/07/2014

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 02/06/2014

JanOne Inc. (JAN) - UPLOAD

  • SEC Filings
  • 01/27/2014

JanOne Inc. (JAN) - CORRESP

  • SEC Filings
  • 01/10/2014

JanOne Inc. (JAN) - UPLOAD

  • SEC Filings
  • 12/27/2013

JanOne Inc. (JAN) - CT ORDER

  • SEC Filings
  • 11/18/2013

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 11/15/2013

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/23/2013

JanOne Inc. (JAN) - 144/A

  • SEC Filings
  • 08/23/2013

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/15/2013

JanOne Inc. (JAN) - 4/A

  • SEC Filings
  • 08/14/2013

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/14/2013

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 07/24/2013

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 07/24/2013

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/13/2013

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 03/26/2013

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 02/26/2013

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/01/2013

JanOne Inc. (JAN) - 4/A

  • SEC Filings
  • 01/08/2013

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 12/12/2012

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 11/28/2012

JanOne Inc. (JAN) - 4/A

  • SEC Filings
  • 11/27/2012

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 11/27/2012

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 10/02/2012

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/09/2012

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 08/09/2012

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/14/2012

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 03/29/2012

JanOne Inc. (JAN) - EFFECT

  • SEC Filings
  • 03/20/2012

JanOne Inc. (JAN) - POS AM

  • SEC Filings
  • 03/14/2012

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 03/06/2012

JanOne Inc. (JAN) - 3/A

  • SEC Filings
  • 03/01/2012

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 02/29/2012

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/03/2012

JanOne Inc. (JAN) - S-8

  • SEC Filings
  • 08/31/2011

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/04/2011

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 08/04/2011

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/16/2011

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 03/31/2011

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/09/2011

JanOne Inc. (JAN) - UPLOAD

  • SEC Filings
  • 02/02/2011

JanOne Inc. (JAN) - CORRESP

  • SEC Filings
  • 01/07/2011

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 01/06/2011

JanOne Inc. (JAN) - UPLOAD

  • SEC Filings
  • 12/08/2010

JanOne Inc. (JAN) - CORRESP

  • SEC Filings
  • 11/22/2010

JanOne Inc. (JAN) - D

  • SEC Filings
  • 11/17/2010

JanOne Inc. (JAN) - UPLOAD

  • SEC Filings
  • 11/02/2010

JanOne Inc. (JAN) - SC 13D

  • SEC Filings
  • 10/25/2010

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/17/2010

JanOne Inc. (JAN) - EFFECT

  • SEC Filings
  • 07/30/2010

JanOne Inc. (JAN) - 424B3

  • SEC Filings
  • 07/29/2010

JanOne Inc. (JAN) - S-3/A

  • SEC Filings
  • 05/19/2010

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/17/2010

JanOne Inc. (JAN) - S-3

  • SEC Filings
  • 05/06/2010

JanOne Inc. (JAN) - SC 13D

  • SEC Filings
  • 04/26/2010

JanOne Inc. (JAN) - D

  • SEC Filings
  • 04/08/2010

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 04/01/2010

JanOne Inc. (JAN) - CT ORDER

  • SEC Filings
  • 03/24/2010

JanOne Inc. (JAN) - SC 13D

  • SEC Filings
  • 03/09/2010

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/01/2010

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 12/31/2009

JanOne Inc. (JAN) - S-8

  • SEC Filings
  • 12/17/2009

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/13/2009

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 04/02/2009

JanOne Inc. (JAN) - 4/A

  • SEC Filings
  • 04/01/2009

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 04/01/2009

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 04/01/2009

JanOne Inc. (JAN) - SC 13D

  • SEC Filings
  • 03/11/2009

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 01/23/2009

JanOne Inc. (JAN) - SC 13D

  • SEC Filings
  • 12/04/2008

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 04/11/2008

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 04/02/2008

JanOne Inc. (JAN) - UPLOAD

  • SEC Filings
  • 03/31/2008

JanOne Inc. (JAN) - UPLOAD

  • SEC Filings
  • 03/28/2008

JanOne Inc. (JAN) - CORRESP

  • SEC Filings
  • 03/24/2008

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 03/07/2008

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/08/2008

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 01/24/2008

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 01/11/2008

JanOne Inc. (JAN) - CORRESP

  • SEC Filings
  • 01/09/2008

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 01/07/2008

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 12/07/2007

JanOne Inc. (JAN) - UPLOAD

  • SEC Filings
  • 11/27/2007

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 11/09/2007

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 10/09/2007

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/24/2007

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/20/2007

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/09/2007

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 06/04/2007

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 06/01/2007

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/25/2007

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/23/2007

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/16/2007

JanOne Inc. (JAN) - ARS

  • SEC Filings
  • 04/09/2007

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 04/06/2007

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 04/06/2007

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 04/06/2007

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/09/2007

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 01/12/2007

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 10/06/2006

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 09/05/2006

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 07/07/2006

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 06/14/2006

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/19/2006

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/12/2006

JanOne Inc. (JAN) - ARS

  • SEC Filings
  • 04/05/2006

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 04/05/2006

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 03/31/2006

JanOne Inc. (JAN) - SC 13G

  • SEC Filings
  • 02/10/2006

JanOne Inc. (JAN) - SC 13G

  • SEC Filings
  • 02/03/2006

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 01/27/2006

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 11/23/2005

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 11/18/2005

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/31/2005

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/22/2005

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 08/11/2005

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/10/2005

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 08/08/2005

JanOne Inc. (JAN) - UPLOAD

  • SEC Filings
  • 07/18/2005

JanOne Inc. (JAN) - S-8

  • SEC Filings
  • 06/29/2005

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 06/22/2005

JanOne Inc. (JAN) - CORRESP

  • SEC Filings
  • 06/17/2005

JanOne Inc. (JAN) - 4/A

  • SEC Filings
  • 05/25/2005

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/24/2005

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/19/2005

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/18/2005

JanOne Inc. (JAN) - 424B3

  • SEC Filings
  • 04/22/2005

JanOne Inc. (JAN) - S-2/A

  • SEC Filings
  • 04/21/2005

JanOne Inc. (JAN) - CORRESP

  • SEC Filings
  • 04/21/2005

JanOne Inc. (JAN) - CORRESP

  • SEC Filings
  • 04/20/2005

JanOne Inc. (JAN) - S-2/A

  • SEC Filings
  • 04/19/2005

JanOne Inc. (JAN) - CORRESP

  • SEC Filings
  • 04/19/2005

JanOne Inc. (JAN) - S-2/A

  • SEC Filings
  • 04/15/2005

JanOne Inc. (JAN) - ARS

  • SEC Filings
  • 04/04/2005

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 04/01/2005

JanOne Inc. (JAN) - UPLOAD

  • SEC Filings
  • 03/09/2005

JanOne Inc. (JAN) - S-2

  • SEC Filings
  • 02/25/2005

JanOne Inc. (JAN) - SC 13G

  • SEC Filings
  • 02/14/2005

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/10/2005

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 01/21/2005

JanOne Inc. (JAN) - REGDEX

  • SEC Filings
  • 01/05/2005

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 12/10/2004

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 06/25/2004

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 06/25/2004

JanOne Inc. (JAN) - 3

  • SEC Filings
  • 06/25/2004

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/24/2004

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 05/11/2004

JanOne Inc. (JAN) - 4

  • SEC Filings
  • 04/14/2004

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 03/26/2004

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/04/2004

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 03/21/2003

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/03/2003

JanOne Inc. (JAN) - S-8 POS

  • SEC Filings
  • 09/04/2002

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 03/22/2002

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 01/29/2002

JanOne Inc. (JAN) - S-8 POS

  • SEC Filings
  • 12/03/2001

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 03/23/2001

JanOne Inc. (JAN) - SC 13D/A

  • SEC Filings
  • 02/14/2001

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 01/22/2001

JanOne Inc. (JAN) - SC 13G

  • SEC Filings
  • 04/14/2000

JanOne Inc. (JAN) - S-8

  • SEC Filings
  • 03/28/2000

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 03/24/2000

JanOne Inc. (JAN) - SC 13D

  • SEC Filings
  • 03/16/2000

JanOne Inc. (JAN) - SC 13D

  • SEC Filings
  • 02/10/2000

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/02/2000

JanOne Inc. (JAN) - S-8 POS

  • SEC Filings
  • 12/30/1999

JanOne Inc. (JAN) - 424B2

  • SEC Filings
  • 07/09/1999

JanOne Inc. (JAN) - S-2

  • SEC Filings
  • 06/21/1999

JanOne Inc. (JAN) - SC 13D

  • SEC Filings
  • 04/09/1999

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 03/26/1999

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 03/10/1999

JanOne Inc. (JAN) - SC 13D

  • SEC Filings
  • 02/12/1999

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/04/1999

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 06/09/1998

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 03/24/1998

JanOne Inc. (JAN) - PRE 14A

  • SEC Filings
  • 03/12/1998

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/13/1998

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/12/1998

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/11/1998

JanOne Inc. (JAN) - S-8 POS

  • SEC Filings
  • 06/05/1997

JanOne Inc. (JAN) - S-8

  • SEC Filings
  • 06/05/1997

JanOne Inc. (JAN) - DEF 14A

  • SEC Filings
  • 03/24/1997

JanOne Inc. (JAN) - PRE 14A

  • SEC Filings
  • 03/14/1997

JanOne Inc. (JAN) - SC 13G

  • SEC Filings
  • 02/14/1997

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/13/1997

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/10/1997

JanOne Inc. (JAN) - 424B1

  • SEC Filings
  • 11/12/1996

JanOne Inc. (JAN) - S-3

  • SEC Filings
  • 11/04/1996

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 07/10/1996

JanOne Inc. (JAN) - SC 13G

  • SEC Filings
  • 02/14/1996

JanOne Inc. (JAN) - SC 13G/A

  • SEC Filings
  • 02/14/1994
Press Releases
StockPrice Release
More Headlines
News

JanOne Inc. added to the Russell Microcap® Index

  • LAS VEGAS , June 3, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that it has been added to the Russell Microcap® Index. The Russell Microcap® Index was launched on June 1, 2005 and measures the performance of the microcap segment of the US Equity market and consists of 1,000 securities, including Virgin Galactic HLDG, Skye Bioscience, Bitcoin Depot Inc., Core Scientific, Hut 8 Corp., and Sonder Holdings Inc., to name a few.
  • 06/03/2024

ALT 5 Sigma, a wholly-owned subsidiary of JanOne to Present at the iFX Expo, the World's largest online trading conference and tradeshow

  • LAS VEGAS, May 28, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN) a multidisciplinary organization with a focus on healthcare and fintech, announced today that its Fintech subsidiary, ALT 5 Sigma, will be presenting at the iFX Expo, the World's largest online trading conference and tradeshow held on June 18 until June 20 in Limassol, Cyprus. https://cyprus2024.ifxexpo.com/ The iFX Expo brings together thousands of C-Level Executives and Industry Peers from 120 countries.
  • 05/28/2024

JanOne Closes Acquisition of ALT 5 Sigma Inc., a Leading Next Generation Blockchain Fintech

  • LAS VEGAS , May 16, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN) announced today it has closed its previously announced acquisition of blockchain financial technology provider, ALT 5 Sigma Inc., and each of its wholly-owned subsidiaries. Launched in 2018, ALT 5 is a fintech that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm.
  • 05/16/2024

JanOne Regains Compliance with Nasdaq's Listing Requirements

  • LAS VEGAS, March 15, 2024 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, today announced that on March 13, 2024 it received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market Inc. ("Nasdaq") indicating that the Company had regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the "Minimum Bid Price Requirement"). As previously announced, the Company received a notification letter from Nasdaq on September 11, 2023, indicating that the closing bid price per share had been below $1.00 for a period of 30 consecutive business days and that the Company did not meet the Minimum Bid Price Requirement.
  • 03/15/2024

Why Is JanOne (JAN) Stock Up 40% Today?

  • JanOne (NASDAQ: JAN ) stock is on the rise Thursday despite a lack of news from the clinical-stage biopharmaceutical company. There haven't been any news press releases of filings with the Securities and Exchange Commission (SEC) from the company that would cause today's rally.
  • 11/09/2023

JanOne to Present at the Dawson James 8th Annual Investment Conference

  • Chief Medical Officer Dr. Amol Soin will explain innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Sept. 21, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the Dawson James Securities 8th Annual Investment Conference in Jupiter, Florida.
  • 09/21/2023

JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference

  • Chief Medical Officer Dr. Amol Soin will discuss innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Aug. 31, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the H.C. Wainwright 25 th  Annual Global Investment Conference in New York City.
  • 08/31/2023

JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

  • The Broad Patent Coverage is a Major Milestone for the Commercial Success of Jan123 LAS VEGAS , Aug. 29, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has earned a US patent for its innovative formulation of low-dose naltrexone, Jan123, for treating pain. The Broad Patent Coverage is a Major Milestone for the Commercial Success of Jan123  Jan123 is being developed to treat complex regional pain syndrome (CRPS), a rare and often life-altering condition characterized by severe pain and hypersensitivity to touch.
  • 08/29/2023

JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting

  • Abstract explained Jan101's statistically significant reduction in pain and improvement in nerve conduction velocity in prior Phase II study. LAS VEGAS , Aug. 25, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, has won a prestigious "Best Abstract" award for reporting that JanOne's treatment for diabetic neuropathy showed both effectiveness against pain and potential to improve nerve function.
  • 08/25/2023

JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules

  • LAS VEGAS, Aug. 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 899,348 shares of the Company's common stock (or prefunded warrants in lieu thereof) at a purchase price of $0.8811 per share of common stock (or prefunded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase 899,348 shares of common stock at an exercise price of $0.7561 per share.
  • 08/22/2023

JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules

  • LAS VEGAS , Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 899,348 shares of the Company's common stock (or prefunded warrants in lieu thereof) at a purchase price of $0.8811 per share of common stock (or prefunded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase 899,348 shares of common stock at an exercise price of $0.7561 per share.
  • 08/18/2023

JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting

  • JAN101 Showed Statistically Significant Reduction in Pain and Improvement in Nerve Conduction Velocity in Prior Phase II study. LAS VEGAS , Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present prior data on Jan101's randomized double blind placebo-controlled trial in diabetic neuropathy patients.
  • 08/18/2023

Penny Stocks To Watch: Why TOUR, JAN, ENDP, BRDS & WEJO Stock Are Moving

  • Penny stocks to watch with news The post Penny Stocks To Watch: Why TOUR, JAN, ENDP, BRDS & WEJO Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 06/28/2022

Best Penny Stocks to Buy Now? 3 to Watch This Week

  • Can these penny stocks make gains this month? The post Best Penny Stocks to Buy Now?
  • 06/07/2022

Why JanOne Shares Are Skyrocketing Today

  • JanOne Inc (NASDAQ: JAN) shares are trading higher by 42.40% at $3.56 after the company announced that a patent was issued that covers a method of improving nerve function using JAN101. JAN101 (formerly known as TV1001SR), is a potential treatment for peripheral artery disease (PAD), a.
  • 06/07/2022

Why JanOne Shares Are Trading Higher Today

  • JanOne Inc (NASDAQ: JAN) sold all of the assets, and none of the liabilities, of GeoTraq Inc., its wholly-owned subsidiary, to SPYR Inc (OTC: SPYR) for an aggregate of $13.5 million. The purchase price is payable in cash and shares of SPYR's common stock.
  • 05/31/2022

JanOne Subsidiary Gets $1.6M Recycling Contract In Virginia, North Carolina

  • JanOne Inc (NASDAQ: JAN) subsidiary ARCA Recycling, Inc. has received a contract to provide appliance recycling services to customers of a major electric utility in Virginia and North Carolina. The total value of the contract awarded is estimated to be ~$1.6 million.
  • 12/16/2021

JanOne Enters Option Agreement For Rights To Novel Strategy To Reduce Methamphetamine Use

  • JanOne Inc (NASDAQ: JAN) has acquired an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the Translocator Protein 18 kDa (TSPO).  The agreement with LSU Health Shreveport and other intellectual property relating to TSPO's role in treating meth use disorder (MUD) provides JanOne with an opportunity to identify new drugs to enhance TSPO activity.
  • 12/07/2021

ARCA Recycling, a Subsidiary of JanOne Inc., Sees Major Increase in Appliance Replacement Contracts, Estimated to Push Revenue of Replacement Programs to Nearly $20 Million, in Addition to Recycling Business

  • MINNEAPOLIS, Oct. 19, 2021 /PRNewswire/ -- ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), has seen major growth in its appliance replacement programs throughout the past 12 months, with the addition of new contracts signed this year that total more than $3 million. It is estimated that these new contracts could increase ARCA's revenue from the replacement programs to approximately $20 million in 2021.
  • 10/19/2021

ARCA Recycling, a Subsidiary of JanOne Inc., Opens New Pennsauken, NJ, Recycling Center, Launches New Recycling Programs

  • MINNEAPOLIS, Sept. 30, 2021 /PRNewswire/ -- ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), opened a new appliance recycling center last month in Pennsauken, New Jersey.
  • 09/30/2021

JanOne Encouraged By Recent FDA Communications Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate JAN101

  • LAS VEGAS, Sept. 28, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company that focuses on the development of treatments for conditions that cause severe pain – in conjunction with its continuing focus on the development of drugs with non-addictive, pain-relieving properties – today announced that it is revising its development strategy based on recent communications with the U.S. Food and Drug administration (FDA) for its upcoming clinical trial of lead drug candidate JAN101 as a treatment for Peripheral Artery Disease (PAD).
  • 09/28/2021

JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients

  • LAS VEGAS, July 22, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has selected CPC Clinical Research (CPC), a full-service academic research organization (ARO), as manager for its upcoming Phase 2b clinical trial of lead product candidate JAN101 for treating Peripheral Artery Disease (PAD). CPC will be responsible for the planning, organization, day-to-day execution, and management of the Company's study, and will collaborate with JanOne's appointed regulatory partner Avania, announced last month.
  • 07/22/2021

JanOne Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites

  • LAS VEGAS, June 23, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that its clinical packaging partner Xerimis has received the bottled clinical batch of JAN101 for the upcoming Phase 2b trial for treating Peripheral Artery Disease (PAD) and is readying the supply for labeling and distribution to clinical sites throughout the U.S.  "We are pleased to report that our clinical supply of JAN101 is now ready for near-term release to our expected clinical trial sites in the upcoming Phase 2 clinical trial," said Tony Isaac, President and Chief Executive Officer of JanOne. "We are fully prepared and look forward to FDA approval of our new protocol.
  • 06/23/2021

JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. to Scientific Advisory Board

  • LAS VEGAS, June 15, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders, Ph.D.
  • 06/15/2021

JanOne Engages DC Consulting LLC for Government and Private Sector Initiatives

  • LAS VEGAS, June 10, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has engaged the services of DC Consulting LLC, a strategy and management consulting firm specializing in government affairs, regulatory guidance, marketing strategy, and public relations services relating to healthcare, pharmaceuticals, drug policy and prevention, law enforcement, and building healthy communities. DC Consulting was founded by former public officials James W.
  • 06/10/2021

JanOne Announces Closing of $6.0 Million Common Stock Offering

  • LAS VEGAS, Feb. 2, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the closing of previously announced its securities offering with...
  • 02/02/2021

JanOne Prices $6.0 Million Common Stock Offering

  • LAS VEGAS, Jan. 29, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced it has entered into a securities purchase agreement with...
  • 01/29/2021

JAN Stock: JanOne Shares Skyrocket as Part of Reddit Run-Up Fever

  • JanOne (JAN) stock is soaring higher Thursday morning as it joins other stocks being boosted by Reddit and other social media users. The post JAN Stock: JanOne Shares Skyrocket as Part of Reddit Run-Up Fever appeared first on InvestorPlace.
  • 01/28/2021

JAN Stock Price Increases Over 198% Pre-Market: Why It Happened

  • The stock price of Janone Inc (NASDAQ: JAN) has increased over 190% pre-market today. This is why it happened.
  • 01/28/2021

JanOne Inc. (JAN) CEO Tony Isaac on Drug Candidate JAN101 - Telebriefing and Corporate Update Call Transcript

  • JanOne Inc. (NASDAQ:JAN) Telebriefing and Corporate Update Call August 25, 2020 16:15 ET Corporate Participants Tony Isaac - Chief Executive Officer Tony Giordano - Chief Scientific Officer Amol Soin - Chief Medical Officer Conference Call Participants Jeremy Roe - Integra Robert Carlson - Janney Montgomery Scott Presentation Operator Good afternoon everyone and thank you for joining us for the JanOne Telebriefing and Corporate Update Call.
  • 08/25/2020

JanOne to Present at The LD 500 Virtual Conference

  • JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it will be presenting at the 12th Annual LD 500 Conference on Thursday, September 3, 2020 at 3:00 PM ET. Tony Giordano, PhD, Chief Scientific Officer of JanOne, will present virtually to an online audience.
  • 08/19/2020

/C O R R E C T I O N -- JanOne/

  • JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, together with its manufacturing partner, has successfully completed the formulation of JAN101, its potential treatment for Peripheral Artery Disease (PAD) expected to soon be in Phase 2b trials. In addition, JAN101 is planned for use to treat COVID-19 vascular complications pending approval of the IND submission, expected to be completed in late August 2020.
  • 08/11/2020

JanOne Engages CATO SMS, a World-Leading CRO, to Assist in the Development of JAN101 to Treat COVID-19 Vascular Complications

  • JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has entered into an agreement with CATO SMS, a world-leading, international regulatory and clinical contract research organization (CRO). CATO SMS will assist JanOne in expanding its current FDA authorized Investigational New Drug (IND) for JAN101, an oral, sustained release formulation of sodium nitrite, to treat vascular complications to potentially restore endothelial cell function in COVID-19 patients. In addition, JAN101 is expected to enter Phase 2b trials in early 2021 to treat Peripheral Artery Disease (PAD).
  • 08/06/2020

JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101

  • JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, announces a internal name change for its current drug candidate from TV1001SR to JAN101, soon to enter Phase 2b clinical trials as a potential treatment Peripheral Artery Disease (PAD). The name change will be effective immediately and will be used in all its current and future clinical trials, Indications for a New Drug, clinical and research studies planned to be conducted in the future.
  • 08/04/2020

JanOne bolsters its scientific advisory board with two leaders in the medical field for vascular regeneration and interventional pain

  • JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with non-addictive pain-relieving properties has added two members to its impressive scientific advisory board. John Cooke, MD, PhD will contribute his esteemed depth of vascular expertise to help guide the success of our clinical therapeutic for the treatment of PAD. Alan Kaye, MD, PhD, is an internationally renowned anesthesiologist and pharmacologist whose pain management research and clinical formulation expertise will play a critical role in advancing our efforts to bring non-addictive pain solutions to market.
  • 07/30/2020

3 ETFs For This Week's Earnings Parade

  • Second-quarter earnings season continues in force this week — and it hasn't been to bad so far on a statistical basis. To date, 26% of the companies in the...
  • 07/27/2020

JanOne Receives FDA Authorization for Transfer of Investigational New Drug (IND) Application for its Sodium Nitrite Tablets

  • JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain-relieving properties, has received confirmation from the Federal Food and Drug Administration (FDA) for the investigational new drug (IND) sponsorship transfer covering its sodium nitrite tablets previously held by Soin Neuroscience. The sodium nitrite sustained release tablet is the clinical candidate TV1001SR, formulated to treat PAD and other vascular conditions. Manufacturing of TV1001SR is underway and phase 2b trials for PAD are expected to begin later this year. There is no current treatment for PAD and over 8.5 million Americans suffer from the disease.
  • 07/21/2020

The perils of waiting 10 days or more to get a coronavirus test result: ‘It’s only marginally better than not doing the testing’

  • When people first started showing signs of coronavirus in the U.S. in March they were told they needed special permission to get tested. If they didn’t fit...
  • 07/17/2020

Dr. Rakesh Patel, internationally recognized scientist in nitric oxide and redox biology, and Dr. Timothy Ness, a pain mechanisms and medication expert, join JanOne's Scientific Advisory Board

  • JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with non-addictive pain-relieving properties, continues to broaden the medical and clinical competency of its scientific advisory board. We are proud to announce the addition of two renowned researchers from the University of Alabama at Birmingham, Rakesh Patel, PhD, and Timothy Ness, MD, PhD. Dr. Patel lends significant scientific knowledge in molecular and cellular pathology and Dr. Ness brings an extensive pain research portfolio with focus on mechanisms of pain for various indications.
  • 07/08/2020

The Online Shopping Expert Reveals Exciting Expansion Plans

  • Already recognised as one of the UK’s leading platforms for savvy online shoppers, the company will now amplify its discount codes categories.
  • 07/08/2020

One of the nation's most renowned pain experts, Dr. Edgar Ross, joins JanOne's Scientific Advisory Board

  • JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with non-addictive pain-relieving properties announced today that Edgar Ross, MD will join the company's scientific advisory board. Dr. Ross is the current Director of the Pain Management Center at Brigham and Women's Hospital and associate professor of anesthesia at Harvard Medical School. He brings over 40 years of experience in the medical field and is a highly regarded pain specialist. Among his many accomplishments, Dr. Ross has published over 100 manuscripts on pain management, participated in numerous pain-related clinical trials for some of the world's top pharmaceutical companies, and served as Chairman of Pfizer's medical and academic partnership on pain.
  • 06/30/2020

These 5 giant stocks are driving the U.S. market now, but bigger is not always better

  • Powerful stock-market leaders ultimately take a fall, writes Mark Hulbert.
  • 06/26/2020

JanOne taps distinguished chemist Dr. Doug Flanagan as chief formulation advisor

  • JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, continues to build a world-class team of biopharma experts with the addition of Douglas Flanagan, PhD as the company's chief formulation advisor. Dr. Flanagan will work directly with CoreRX, JanOne's manufacturing partner to ensure the integrity of TV1001SR, the company's clinical candidate for treating Peripheral Artery Disease (PAD) expected soon to enter phase 2 trials. He will also play an integral role for the potential identification and advancement of other clinical candidates to treat pain as the company hopes to broaden its pipeline in the near future.
  • 06/25/2020

JanOne Launches Strategic Alternatives Process for Legacy Businesses

  • JanOne Inc. (Nasdaq:JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, today announced the commencement of a strategic alternative process for its legacy businesses in an effort to enhance shareholder value. This review process will be conducted with the assistance of the company's financial and legal advisors and will consider the full range of potential strategic alternatives with respect to its legacy businesses. This will include but is not limited to, acquisitions, business combinations, joint ventures, spinoffs, public and private capital raises, recapitalization, and sale transaction options.
  • 06/18/2020

Entry Points Count

  • Intraday volatility for stocks, whether $10 numbers or growthies selling in three digits does range between 5% and 10%. You see such action in U.S. Steel, Alcoa, Energy Transfer, General Electric and Ford Motor – all under $10 paper, but with few friends.
  • 06/18/2020

Future of `Tejas’ with Indigenous Kaveri Engine: A long way to go

  • “Kaveri is a low bypass twin-spool turbofan jet engine which was slated to provide an 80 KN power pack and adequate ‘thrust to weight’ ratio required by a modern fighter jet configuration,” explained an aeronautical engineer.
  • 06/14/2020

Here are the biggest stock-market bets among institutional and retail investors, ranked

  • What it all means is a little harder to figure out...
  • 06/09/2020

What a great time to start a new business

  • Downturns and bear markets present a great opportunity for entrepreneurs to start a new business.
  • 05/28/2020

Dow futures fall as Wall Street weighs states’ reopenings, China-U.S. tensions

  • U.S. stock-index futures fall sharply in thin trading Sunday evening as investors contend with state reopenings amid signs of brewing conflict between China...
  • 05/04/2020

Beaten-up value stocks are offering opportunities of a generation, fund manager says

  • One fund manager is convinced value stocks will come back. Here’s where he is invested.
  • 04/29/2020

GE And Ford: 2 Of The Weakest Charts In April

  • GE and Ford have experienced rotten March-April trends in trading action. Despite a major bounce higher in the U.S. stock market, the two blue-chips remain unde
  • 04/29/2020

ACB, MYGN among premarket losers

  • Salarius Pharmaceuticals (NASDAQ:SLRX) -53% after pricing equity offering.Resonant (NASDAQ:RESN) -31% after pricing equity offering.Myriad Genetics (NASDAQ:MYGN) -30% on Q2 earnings.Zogenix (NASDAQ:ZG
  • 02/07/2020

100 Biggest Movers From Yesterday

  • Gainers Schrodinger, Inc. (NASDAQ: SDGR) shares jumped 68.5% to close at $28.64 on Thursday after the company priced its IPO at $17 per share. Yield10 Bioscience, Inc. (NASDAQ:...
  • 02/07/2020

Mid-Morning Market Update: Markets Open Higher; Twitter Beats Revenue Estimates

  • Following the market opening Thursday, the Dow traded up 0.14% to 29332.00 while the NASDAQ rose 0.39% to 9,545.86. The S&P also rose, gaining 0.27% to 3,343.84. Leading and...
  • 02/06/2020

JanOne strikes agreement with CoreRx, a leading cGMP contract manufacturer, for Phase 2b clinical formulation and development

  • JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, has executed a manufacturing agreement for the formulation and manufacturing of TV1001SR, a treatment for Peripheral Artery Disease (PAD). PAD affects over 8.5 million people in the United States and there are currently no direct treatments for PAD on the market today. Research Market Future (MRFR) values the PAD market at $3.47 billion in the United States by 2023.1"
  • 02/06/2020

Amol Soin, MD, One Of The Nation's Leading Pain Experts, Named As JanOne's Chief Medical Officer

  • JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties, announced the addition of Amol Soin, MD as the company's chief medical officer. Dr. Soin has been recognized multiple times as one of America's Top Doctors and is the recipient of the Patient's Choice Award, an honor given only to the top 1% of physicians in the country.
  • 01/28/2020

JanOne Scientific Advisory Board Chair and Leading Pain Expert Featured on ABC-7 WJLA America This Week

  • JanOne Inc. (NASDAQ:JAN) Scientific Advisory Board Chair, Dr. Christopher Kevil sat down with Eric Bolling, JanOne's President and Chairman and host of America This Week, to discuss the effects of the company's lead drug candidate, TV1001SR, for the treatment of peripheral artery disease (PAD) and associated pain. Dr. Kevil was joined by renowned pain expert, Dr. Amol Soin, and both provided their insights and perspective for an approach that treats the mechanisms of a disease process, such as in PAD, and concurrently can have significant pain relieving qualities. Of particular interest was how in prior studies TV1001SR was able to treat both the underlying condition and the associated pain with no addictive repercussions. The company believes that this could mitigate the need for prescription opioids that often come with a risk for addiction, when patients are suffering from severe pain.
  • 01/23/2020

Leading Cardiovascular Researcher And PAD Treatment Pioneer, Dr. Christopher Kevil, To Chair JanOne Scientific Advisory Board

  • JanOne Inc. (NASDAQ:JAN) appoints Christopher Kevil, Ph.D., a pioneer in nitrite based PAD treatment, to lead its scientific advisory board. In this role, Dr. Kevil will chair the Company's scientific advisory board to advise on drug development and technology strategy, assist with clinical research, and help to advance its lead candidate TV1001SR, for the treatment of PAD. Dr. Kevil is considered a foremost expert in the development and analysis of various small molecules, biologics, disease indications, pharmaceutical, medical device, and drug delivery systems.
  • 01/16/2020

History will repeat itself when it comes to stocks in 2020, Goldman Sachs says

  • The signing of a “phase one” trade deal between the U.S. and China after months of negotiations and tensions looks set to boost stocks further.
  • 01/14/2020

The big booths of CES 2020

  • From spectacular bending screens to Spider-Man, from giant slides to somewhere quiet to sit, here are the most extravagant booths from this year's tech shindig in Las Vegas.
  • 01/08/2020

Why buying and selling a house could soon be as simple as trading stocks

  • Artificial intelligence in housing won’t just eliminate Realtors. It could completely change the way we buy, sell and live.
  • 12/29/2019

JanOne Names Tony Giordano, Ph.D., as Chief Scientific Officer

  • JanOne Inc. (NASDAQ:JAN) a company focused on reducing opioid addiction by finding treatments for conditions accompanied by pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties, announced the hiring of Tony Giordano, Ph.D. to serve as its Chief Scientific Officer.
  • 12/03/2019

JanOne Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD)

  • JanOne Inc. (NASDAQ: JAN), a company focused on reducing opioid addiction by finding treatments for conditions accompanied by pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties, today announced a licensing agreement for TV1001SR, a treatment for Peripheral Artery Disease, commonly called PAD. The agreement with LSU Health Shreveport, UAB Research Foundation, and TheraVasc, Inc., gives JanOne a worldwide, exclusive license for TV1001SR along with a portfolio of 30 patents and other intellectual property relating to the sustained release of sodium nitrite.
  • 11/25/2019

JanOne Names America This Week Host And Financial Commentator Eric Bolling As President And Chairman

  • LAS VEGAS, Sept. 12, 2019 /PRNewswire/ -- JanOne, Inc. (NASDAQ: JAN), a newly launched initiative with the focused intent of offering innovative, actionable solutions to end the opioid crisis, is proud to name host of America This Week and financial commentator Eric Bolling as its President and Chairman. As one personally affected by the opioid scourge, Bolling has dedicated himself to fighting the opioid epidemic by executing the mission of JanOne: To help to end the opioid crisis by, among other things, developing revolutionary pain medications to replace today's highly addictive and often fatal opioids. "I am elated to become part of JanOne and to help fulfill the mission of developing alternative, non-opioid pain drugs," Bolling said.
  • 09/12/2019

ARCA Now Doing Business as JanOne, Trades Under New Nasdaq Ticker Symbol JAN

  • LAS VEGAS, Sept. 11, 2019 /PRNewswire/ -- Appliance Recycling Centers of America, Inc. (NASDAQ: JAN) today announced that, on September 10, 2019, the company has been renamed JanOne Inc. and, effective this morning, now trades under the ticker symbol JAN, with a new CUSIP number (47089W 104). The company's new name, JanOne, expresses the start of a new day in the fight against the opioid epidemic. January One is the first day of a New Year – a day of optimism, resolution, and hope.  JanOne affirms the company's strategic commitment to fresh thinking and innovative means to assist in ending the worst drug crisis in our nation's history.
  • 09/11/2019

Appliance Recycling Centers of America (a) ARCA Inc (ARCI) hits 52-week high | AlphaStreet

  • Shares of Appliance Recycling Centers of America (NASDAQ: ARCI) opened up about 80% at $8.50 today reaching a new 52-week high as its subsidiary GeoTraq announced the transition from GSM to LTE-M/NB-IoT connectivity, creating a new class of Mobile IoT modules. ARCI stock had more than doubled (up 111%) since the beginning of 2019 and had gained 21% in the past 12 months.
  • 04/25/2019

Half of investment-grade bonds are only one step away from junk status

  • Companies binged on cheap credit, and they’re about to pay the price.
  • 01/08/2019

You and I Are Not Doomed: Market Recon

  • But we are going to have to work harder from now on.
  • 01/18/2018

What Is the New York Stock Exchange? | The Motley Fool

  • The New York Stock Exchange is the largest and oldest stock exchange in the United States.
  • 08/11/2016
Unlock
JAN Ratings Summary
JAN Quant Ranking